The global trial, KARDIA-2, involved 663 people with high blood pressure whose condition wasn't being well managed with their standard treatment. In the trial, patients were given an injection of a ...

This injection reduces the production of angiotensin, a hormone that increases blood pressure, in the body.

The injection is given under the skin. The next steps for zilebesiran involve another Phase 2 study, KARDIA-3, to see if this treatment has potential to be used to treat people with high blood ...

The development, researchers say, could fundamentally change how hypertension is managed, particularly at a time when control rates remain alarmingly low.

A new Lancet review suggests that just two injections a year could transform hypertension treatment, offering a long acting and potentially more effective approach to managing high blood pressure.